Informe de análisis de tamaño, participación y tendencias del mercado mundial de lesiones agudas de la médula espinal: descripción general de la industria y pronóstico hasta 2031

Análisis del mercado de lesiones agudas de la médula espinal

El mercado mundial de lesiones agudas de la médula espinal (ASCI) está experimentando un crecimiento significativo, impulsado por una mayor conciencia y avances en las opciones de tratamiento. Como se detalla en un estudio reciente, la incidencia de lesiones de la médula espinal está aumentando, atribuida a factores como accidentes de tráfico, caídas y lesiones relacionadas con el deporte. Esta creciente prevalencia requiere estrategias de gestión eficaces e intervenciones terapéuticas innovadoras, incluidos procedimientos quirúrgicos, rehabilitación y tratamientos farmacológicos como los corticosteroides. El mercado se caracteriza por una variedad de entornos sanitarios, incluidos hospitales y centros de traumatología, que desempeñan un papel fundamental en la atención al paciente. Además, el desarrollo de tecnologías avanzadas para la tracción espinal y las intervenciones quirúrgicas está impulsando la expansión del mercado. Los actores clave en el mercado se están centrando en la investigación y el desarrollo para introducir nuevas terapias destinadas a mejorar los resultados de la recuperación. Además, se espera que el aumento de las inversiones en infraestructura sanitaria y el aumento del gasto sanitario contribuyan positivamente al crecimiento del mercado de ASCI. En general, la combinación de tasas de incidencia en aumento, avances tecnológicos y un sistema sanitario sólido respaldan las perspectivas prometedoras para el mercado mundial de lesiones agudas de la médula espinal en los próximos años.

Tamaño del mercado de lesiones agudas de la médula espinal

El tamaño del mercado mundial de lesiones agudas de la médula espinal se valoró en USD 7,58 mil millones en 2023 y se proyecta que alcance los USD 11,55 mil millones para 2031, con una CAGR del 5,40% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Tendencias del mercado de lesiones agudas de la médula espinal

“ Cada vez más atención a la medicina regenerativa ”

El mercado de las lesiones agudas de la médula espinal (LEME) está experimentando un crecimiento significativo impulsado por los avances en las metodologías de tratamiento y los enfoques terapéuticos innovadores. Una tendencia destacada es el creciente enfoque en la medicina regenerativa, en particular el desarrollo de terapias con células madre destinadas a promover la regeneración neuronal y mejorar la recuperación funcional en pacientes con LEME. Por ejemplo, los ensayos clínicos que evalúan la eficacia de las células madre mesenquimales (MSC) están mostrando resultados prometedores en la restauración de la función motora y la reducción de la discapacidad. Empresas como InVivo Therapeutics están a la vanguardia de esta tendencia, trabajando en dispositivos implantables y biomateriales que apoyan la curación de la médula espinal. Además, los avances en medicamentos neuroprotectores y tecnologías de rehabilitación mejoran aún más los resultados de los pacientes. A medida que aumenta el conocimiento de las LEME y aumenta la demanda de terapias efectivas, se espera que el mercado se expanda, brindando oportunidades para la innovación y la inversión. La integración de estas tendencias será crucial para dar forma al futuro del panorama del tratamiento de las lesiones agudas de la médula espinal .

Alcance del informe y segmentación del mercado de lesiones agudas de la médula espinal     

Acute Spinal Cord Injury Market Definition

Acute spinal cord injury (ASCI) refers to a sudden and often traumatic damage to the spinal cord that results in a loss of function, including mobility and sensation. This type of injury can occur due to various causes, such as motor vehicle accidents, falls, sports injuries, or violent acts. ASCI can lead to partial or complete loss of motor and sensory function below the level of the injury, classified as complete (total loss of function) or incomplete (some preserved function).

Acute Spinal Cord Injury Market Dynamics

Drivers

• Increasing Incidence of Spinal Cord Injuries

The increasing incidence of spinal cord injuries (SCI) significantly drives the acute spinal cord injury market, as factors such as road traffic accidents, sports injuries, falls, and violence contribute to a rising number of cases. For instance, the National Spinal Cord Injury Statistical Center (NSCISC) reported that approximately 17,730 new spinal cord injury cases occur each year in the United States alone, with vehicle accidents accounting for nearly 38% of these injuries, followed by falls (30%) and acts of violence (14%). Such upward trend underscores the urgent need for effective treatments and interventions, propelling advancements in medical technology, rehabilitation services, and pharmaceutical research. As more individuals are affected by acute spinal cord injuries, the demand for specialized care and innovative solutions in this market continues to grow, highlighting the critical role of addressing this public health concern.

• Rising Particularly in Extreme Sports and Recreational Activities

The increase in sports participation, particularly in extreme sports and recreational activities, is a significant driver of the acute spinal cord injury (ASCI) market, as it correlates with a higher incidence of injuries. According to a study published in the American Journal of Sports Medicine, between 1990 and 2010, the incidence of spinal cord injuries among participants in extreme sports, such as snowboarding, skateboarding, and motocross, increased by over 200%. This surge in injuries highlights the risks associated with high-impact sports and emphasizes the growing need for effective treatment options and rehabilitation services tailored for athletes. As more individuals engage in these activities, the demand for specialized medical care, including surgical interventions, physical therapy, and innovative rehabilitation technologies, will continue to rise, fueling the growth of the ASCI market.

Opportunities

• Increasing Advancements in Medical Technology

Advancements in medical technology have significantly transformed the landscape of acute spinal cord injury (ASCI) treatment, presenting a valuable market opportunity. The development of advanced surgical techniques, particularly minimally invasive procedures, allows for reduced tissue damage, shorter recovery times, and less postoperative pain compared to traditional open surgeries. For instance, robotic-assisted surgeries enable surgeons to perform highly precise operations, enhancing accuracy in decompression and stabilization of the spinal cord while minimizing complications. Techniques like endoscopic discectomy exemplify these advancements, allowing for the removal of herniated discs through small incisions, which leads to quicker patient recovery and rehabilitation. As these technologies continue to evolve, they improve surgical outcomes and increase the efficiency of healthcare delivery, thereby expanding the market for ASCI treatments. This shift toward minimally invasive and robotic-assisted surgeries creates significant potential for growth in the ASCI market, as hospitals and healthcare providers seek to adopt these innovations to enhance patient care and optimize resource utilization. The increasing demand for these advanced solutions underscores the importance of ongoing research and investment in medical technology, solidifying it as a critical market opportunity in the management of acute spinal cord injuries.

• Rising Healthcare Expenditures in Both Emerging and Developed Economies

Rising healthcare expenditures in both emerging and developed economies present a significant market opportunity for the acute spinal cord injury (ASCI) sector. Increased healthcare spending enables governments and private entities to invest in improved healthcare infrastructure, ensuring that hospitals and rehabilitation centers are equipped with state-of-the-art technologies and resources. For instance, in countries such as India and Brazil, escalating healthcare budgets have led to the establishment of specialized spinal injury units and rehabilitation facilities that provide comprehensive care tailored to the needs of patients. This enhanced infrastructure facilitates access to advanced treatment options, such as innovative surgical techniques and cutting-edge rehabilitation therapies, thereby improving patient outcomes and recovery rates. Additionally, higher healthcare expenditures promote research and development, paving the way for new therapeutic approaches and technologies that can further benefit ASCI patients. As healthcare systems evolve and prioritize the treatment of spinal cord injuries, the growing financial investment in health services creates a promising market opportunity for stakeholders, including medical device manufacturers, pharmaceutical companies, and rehabilitation service providers, to expand their offerings and cater to an increasing patient population.

Restraints/Challenges

• Variable regulatory environments across different countries

Variable regulatory environments across different countries pose a significant challenge for the global acute spinal cord injury (ASCI) market, creating barriers to the approval and adoption of new treatments and technologies. Each country has its own regulatory framework governing medical devices and pharmaceuticals, which can lead to inconsistencies in the approval process. For instance, while a novel therapeutic intervention may receive rapid approval in one country, it could face lengthy evaluations and additional trials in another, delaying its availability to patients. Such disparity can stifle innovation and limit the introduction of potentially life-saving technologies. Furthermore, companies may be hesitant to invest in research and development for spinal cord injury treatments if they perceive the regulatory landscape as uncertain or burdensome. Such challenges can hinder access to advanced therapies that could significantly improve patient outcomes. As a result, the variable regulatory environments create significant obstacles for the ASCI market, slowing the pace of innovation and potentially leaving patients without the latest and most effective treatment options.

• Significant Expenses Related to Acute Spinal Cord Injury Treatment

High treatment costs present a significant challenge in the management of acute spinal cord injuries (ASCI), impacting patient access to essential services and hindering market growth. The expenses associated with spinal cord injury treatment can be substantial, encompassing costs for emergency surgery, inpatient rehabilitation, outpatient therapies, and long-term care. For instance, in many countries, the total lifetime cost of care for an individual with a spinal cord injury can be prohibitively high, including ongoing medical expenses and the need for assistive devices. Such financial burdens can deter patients from seeking timely treatment, especially in low- and middle-income countries where healthcare resources are limited, and out-of-pocket expenses may be unaffordable. In regions with inadequate insurance coverage or high copayments, many patients may forego necessary surgeries or rehabilitation services, ultimately leading to poorer health outcomes and increased long-term dependency on healthcare systems. As a result, the high costs associated with spinal cord injury care create barriers for patients and pose a significant challenge for the ASCI market, as healthcare providers strive to deliver effective and affordable treatment options amid rising economic pressures.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Acute Spinal Cord Injury Market Scope

The market is segmented on the basis of type, treatment type, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Complete Spinal Cord Injury
• Incomplete Spinal Cord Injury

Treatment Type

• Corticosteroid
• Surgery
• Spinal Traction

End User

• Hospitals
• Trauma Centers

Acute Spinal Cord Injury Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment type, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a leading position in the acute spinal cord injury market, driven by heightened awareness of spinal cord injuries and a well-established healthcare infrastructure. The region benefits from cutting-edge medical technologies, advanced treatment options, and ongoing research initiatives aimed at improving patient outcomes. Additionally, strong support from healthcare organizations and increased public awareness campaigns have contributed to early diagnosis and better treatment accessibility. These factors together create a favorable environment for market growth in North America.

Asia-Pacific is anticipated to experience substantial growth in the acute spinal cord injury market during the forecast period, largely driven by the presence of emerging economies like China, India, and Brazil. These countries are witnessing increased investments in healthcare development and infrastructure, which is enhancing the availability of advanced treatments. Additionally, the rising demand for improved healthcare services, coupled with a growing focus on medical research and innovation, is fueling market expansion in this region. This combination of factors positions Asia-Pacific as a key area for future growth in the spinal cord injury market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Acute Spinal Cord Injury Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Acute Spinal Cord Injury Market Leaders Operating in the Market Are:

• Novartis AG (Switzerland)
• Tenax Therapeutics (U.S.)
• Accure Pharma (U.S.)
• Merz Therapeutics (Germany)
• ReNetX Bio, Inc. (U.S.)
• BioArctic AB (Sweden)
• Biotimeinc (U.S.)
• Kringle Pharma, Inc. (U.S.)
• BioAxone (Canada)
• AO Foundation (Switzerland)
• Pfizer Inc. (U.S.)
• PHARMICELL Co., Ltd (South Korea)
• Vertex Pharmaceuticals Incorporated (U.S.)
• Axoltis (Switzerland)
• Biostar Stem Cell Research and Development (Taiwan)

Latest Developments in Acute Spinal Cord Injury Market

• In September 25, 2023, NervGen Pharma Corporation, a clinical-stage biotech company focused on treatments for nervous system damage, announced that the first participant had been dosed in their landmark Phase 1b/2a placebo-controlled clinical trial for NVG-291, their lead compound for spinal cord injury (SCI)
• En agosto de 2023, Kaneka Corporation, un fabricante internacional de productos químicos con sede en Japón, inició un ensayo clínico de fase I/II para KA-301, un tratamiento para la lesión aguda de la médula espinal derivado de células madre mesenquimales humanas basadas en amnios. Las preparaciones celulares para este ensayo se desarrollaron mediante tecnología respaldada por la Agencia de Ciencia y Tecnología de Japón (JST) en el marco del programa NexTEP
• En julio de 2023, NeuroSolv Therapeutics, con sede en Belfast (Irlanda del Norte) y Baltimore (EE. UU.), se asoció con AscellaHealth LLC, una empresa global de soluciones de farmacia especializada y atención médica. La colaboración tiene como objetivo ampliar el programa de desarrollo de ensayos clínicos de NeuroSolv y agilizar los procesos de aprobación regulatoria, con el objetivo de acelerar el lanzamiento al mercado de su producto, Perineline.
• En junio de 2022, Amneal Pharmaceuticals, Inc. anunció el lanzamiento comercial de LYVISPAH, un producto de gránulos orales de baclofeno aprobado por la FDA (disponible en dosis de 5, 10 y 20 mg) diseñado para tratar la espasticidad asociada con la esclerosis múltiple y otros trastornos de la médula espinal.
• En agosto de 2021, Novartis AG anunció que la FDA había levantado la suspensión parcial de los ensayos clínicos, impuesta originalmente en octubre de 2019, lo que permitió que se reanudaran los ensayos clínicos intratecales (IT) de OAV-101 para pacientes con atrofia muscular espinal (AME).
• En julio de 2021, Mitsubishi Tanabe Pharma Corporation, una empresa farmacéutica global, recibió la designación de vía rápida de la FDA de EE. UU. para MT-3921, un tratamiento en desarrollo para la lesión de la médula espinal.

SKU-65907